Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The stock market staged a lightning-fast recovery, raising eyebrows and expectations. Dan Greenhaus emphasized that rapid rebounds often mirror the speed of previous declines, hinting at the market’s ...

ELRIG, the not-for-profit organisation connecting the global drug discovery community, has announced the keynote speakers for ...

Investing.com -- Moody’s Ratings has assigned an A2 rating to Pfizer Netherlands International Finance B.V. (PNIF BV), a ...

BMO Capital cut Terns Pharmaceuticals' price target from $26 to $15, citing costlier capital conditions despite maintaining ...

Pfizer Inc.’s stock rose handily Tuesday after ... as sales of its COVID-19 medicine Paxlovid plunged by 75% on fading demand. Back To Top ...

Discover what's behind Pfizer's sharp decline, from post-pandemic revenue drops to halted drug development and regulatory ...

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the ...

Awards will also recognise innovation, rising stars from the ECP community, and individuals who have made outstanding ...

Altria's dividend yield is 7%, even as it trades at 11 times estimated earnings over the next 12 months – a 40% premium to ...

With the end of the pandemic, sales of Pfizer’s COVID products, Comirnaty and Paxlovid, came down to around $11 billion in 2024 from $56.7 billion in 2022. In 2025, Pfizer’s revenues from ...

Market pessimism has undervalued Pfizer and Rexford, both offering high yields and overlooked growth potential. Learn more on ...